Table 1.
Patient demography and clinical status of the study participants
| Over all (n = 105) | <5 years (n = 17) | ≥5 to <10 years (n = 49) | ≥10 years (n = 39) | |
|---|---|---|---|---|
| Sex: Male (%) |
61 (58.1%) |
12 (70%) |
29 (59%) |
20(51%) |
| CD4-T cell count |
530 (338–780) |
1051 (528–1154) |
586 (401–768) |
373 (251–578) |
| Median (IQR*) | ||||
| Viral load log copies/mL |
5.24 (4.62-5.66) |
5.56 (5.51-6.05) |
5.12 (4.55-5.55) |
5.2 (4.73-5.63) |
| Median (IQR*) | ||||
| WHO Clinical stage | ||||
| Stage 1 |
40 (38.1%) |
6 (35.3%) |
19 (38.7%) |
15 (38.5%) |
| Stage 2 |
37 (35.2%) |
5 (29.4%) |
19 (38.7%) |
13 (33.3%) |
| Stage 3 |
22 (21%) |
4 (23.5%) |
9 (18.4%) |
9 (23.1%) |
| Stage 4 | 6 (5.7%) | 2 (11.8%) | 02 (4.1%) | 2 (5.1%) |
*IQR: Inter-quartile range.